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Research Paper
Expression of the PlA2 allele
of glycoprotein IIIa and its impact
on platelet function
Christopher N Floyd1, Timothy DWarner2 and Albert Ferro1
Abstract
Background: The platelet fibrinogen receptor represents the final common pathway of platelet activation, and is
formed from two glycoprotein (GP) subunits (GPIIb/IIIa). Carriage of the mutant PlA2 allele of GPIIIa has been
shown to confer an increased risk of cardiovascular events, but published studies have disagreed as to the mechanism
for this association.
Objectives: To assess whether carriage of the PlA2 allele conforms to Mendelian patterns of expression and to identify
whether carriage of the mutant allele modulates platelet function.
Methods: Expression of the PlA2 allele was assessed in both healthy subjects (n¼ 25) and patients with known coronary
artery disease (n¼ 90) through the development and validation of a liquid chromatography, tandem mass spectrometry
(LC-MS/MS) assay. Platelet function was assessed in the patient cohort in response to multiple agonists, and these data
were analysed in the context of the proteomic data.
Results: Expression of the wild-type PlA1 allele and mutant PlA2 alleles was readily quantifiable and conformed to
Mendelian patterns in both healthy and patient cohorts. Patients who were homozygous for the mutant PlA2 allele had
an increased aggregatory response to adenosine diphosphate, collagen, adrenaline, ristocetin, thrombin receptor-activat-
ing peptide 6 and U46619, when assessed using agonist-concentration response curves.
Conclusions: These findings support the hypothesis that carriage of the mutant PlA2 allele mediates an increased risk of
cardiovascular events through the modulation of platelet reactivity.
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Introduction
The ﬁbrinogen receptor is the most abundant integrin
on the platelet surface, and represents the ﬁnal common
pathway of platelet activation, adhesion and aggrega-
tion.1,2 Formed from two glycoprotein (GP) subunits
(GPIIb/IIIa), the receptor binds a combination of
ﬁbrinogen, von Willebrand factor (vWF) and ﬁbronec-
tin in a process that terminates haemorrhage following
vascular injury.3–5 The GPIIIa subunit is polymorphic
with single amino acid substitutions resulting in a
number of stable allelic variants, the PlA1/A2 diallelic
antigen system being one of the more heavily studied
due to its association with neonatal alloimmunity and
an increased risk of cardiovascular events.6–8 The
prevalence of the PlA2 allele varies between ethnic
groups, with a frequency of approximately 1% in
Oriental populations, rising to 15% in Caucasian
populations.9,10
There had been much disagreement as to the extent,
and indeed validity, of any association between carriage
of the mutant PlA2 allele and cardiovascular disease until
recent meta-analyses showed that carriage of the PlA2
allele does indeed confer a moderate increased risk of
both myocardial infarction (n¼ 40,692; OR 1.08, 95%
CI 1.02–1.13; p¼ 0.004) and ischaemic stroke (n¼ 11,873;
OR 1.12, 95% CI 1.03–1.22; p¼ 0.011).11,12 Signiﬁcant
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heterogeneity was observed across these analyses, and it is
unclear whether this represents the challenge of identify-
ing the contribution of a single polymorphism to a multi-
factorial, polygenic pathological process13 or variation in
an individual’s expression of the PlA1/A2 proteins in het-
erozygotes. It is not yet known whether expression of the
PlA1/A2 proteins obey Mendelian rules or whether sub-
jects identiﬁed as genetically heterozygous may in fact
have non-uniform patterns of protein expression. A
non-uniform pattern of expression would be represented
by a heterozygous individual expressing the PlA1/A2 pro-
teins in a ratio that diverges from the 1:1 ratio proscribed
by Mendelian rules. If the ratio of expression was found
to vary signiﬁcantly between heterozygous individuals,
the utility of genomic techniques to quantify the cardio-
vascular risk conferred by heterozygous expression would
be signiﬁcantly impaired. If the allele is to realise any
potential as a biomarker of cardiovascular disease,
either as a standalone test or as part of broader risk strati-
ﬁcation, it is vital to understand its proteomic expression.
Uncertainty also remains as to the aetiology of the
increased risk conferred by carriage of the PlA2 allele.
The mutant allele encodes a single amino acid substi-
tution of proline for leucine adjacent to the ligand bind-
ing site,6 and it has therefore been hypothesised that the
polymorphism leads to increased platelet reactivity.
Studies in static systems have shown no impact of the
polymorphism on ligand binding,14,15 although those
performed in cell culture under conditions of shear
stress have noted enhanced binding to both ﬁbrinogen
and vWF.16,17 The response to platelet agonists has
similarly found to be mixed.14,18 It has also been sug-
gested that carriage of the PlA2 allele leads to aspirin
resistance, a phenomenon that confers increased car-
diovascular risk,19 although a recent meta-analysis
does not support this hypothesis.20
In this study, we have developed a liquid chromatog-
raphy, tandem mass spectrometry (LC-MS/MS) assay to
measure the expression of platelet PlA1/A2 peptides in
both healthy subjects and patients with cardiovascular
disease. The use of a LC-MS/MS assay containing inter-
nal reference peptides provides a truly quantitative meas-
ure of peptide expression. We hypothesise that the
proteomic expression of the PlA1/A2 alleles can be
quantiﬁed using LC-MS/MS, conforms to Mendelian
rules of expression, and that increased cardiovascular
risk conferred by carriage of the PlA2 allele is secondary
to increased levels of platelet reactivity.
Methods
Subject recruitment
Twenty-ﬁve clinically healthy subjects, without per-
sonal or family history of a bleeding disorder, and
having not consumed any medication for at least 14
days, were recruited as the ‘healthy cohort’ to facilitate
the development of the LC-MS/MS assay.
Patients with stable coronary artery disease were
recruited from Guy’s and St Thomas’ NHS
Foundation Trust following an automated search of
the TOMCAT clinical database (Phillips) covering the
period 6 January 2012 to 11 January 2013. A summary
of the recruitment protocol can be seen in Figure 1.
Ninety patients were recruited as the ‘patient cohort’,
and satisﬁed the following inclusion criteria: (i) pres-
ence of angiographic coronary artery disease and (ii)
prescribed daily 75mg aspirin therapy as their sole anti-
platelet agent. Patients were excluded if they had a clin-
ical history suggestive of unstable angina or acute
coronary syndrome (ACS) in the previous four
months.21,22 Ethical approval for the study was
obtained from London-Bloomsbury Research Ethics
Committee (Reference: 11/LO/1371). All participants
were recruited from King’s College London and
Guy’s and St Thomas’ NHS Trust, provided written
informed consent to participate in this study, with the
consent procedure approved by the ethics committee.
Platelet function testing
Blood was drawn by venipuncture into trisodium cit-
rate (ﬁnal concentration 0.32%) from an antecubital
vein, with samples sent for biochemical and haemato-
logical analyses. Whole blood was centrifuged (15min,
200 g) at room temperature (RT) to obtain platelet-
Figure 1. Summary of patient recruitment.
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rich plasma (PRP), with platelet-poor plasma (PPP)
obtained by further centrifugation of PRP (5min,
7000 g, RT). The platelet count of PRP was not
adjusted, and this approach is consistent with current
recommendations.23
Light transmission aggregometry (LTA) was per-
formed in response to arachidonic acid (1.6mM; AA,
Sigma) and adenosine diphosphate (10 mM; ADP,
LabMedics) using a PAP8E aggregometer (Bio/Data
Corporation) as previously described.24 Brieﬂy,
225 mL PRP was incubated for 2min at 37C, before
the addition of 25 mL agonist. Agonist and PRP were
continually mixed by a siliconised stirrer bar generating
a low-shear vortex (1200 r/min), with measurements of
light transmission recorded over 5min. Light transmis-
sion through unstimulated PRP and PPP was cali-
brated to 0% and 100% aggregation, respectively.
Aspirin resistance status in the patient cohort was
assigned based on 20% aggregation on LTA in
response to 1.6mM AA and/or 70% aggregation in
response to 10 mM ADP.25,26
Categorisation of platelet function was performed
using the Optimul assay, which utilises a similar prin-
ciple to LTA, but enables multiple agonist concentra-
tions to be assessed simultaneously.27 Brieﬂy, a 96-well
ﬂat-bottomed plate was prepared with platelet agonists
to achieve the following concentrations on the addition
of 100 mL PRP: AA (0.03–1.6mM), ADP (0.3–30 mM),
collagen (0.1–30 mg/mL; LabMedics), adrenaline
(0.001–100 mM; LabMedics), ristocetin (0.18–2mg/
mL; Helena Laboratories), thrombin receptor-activat-
ing peptide 6 (0.1–30 mM; TRAP-6, Bachem) and
U46619 (0.1–30mM; Cayman Chemical). On addition
of PRP, the plate was immediately placed in a 96-well
plate reader (Tecan Sunrise) and absorbance deter-
mined at 595 nm every 15 s for 16min, between vigor-
ous linear shaking at 37C.
Mass spectrometry
An expanded description on the development and val-
idation of the LC-MS/MS assay is available in the
Supplemental Material.
A selective reaction monitoring (SRM) assay was
developed to enable the absolute quantiﬁcation of
PlA1/A2 peptides through the use of synthetic peptides
as internal reference standards.28,29 The assay was vali-
dated in accordance with standard criteria,30 and the
lower limit of measuring range (LMR) observed to be
20 fmol for both wild-type and mutant peptides.
Peptide quantiﬁcation 20 fmol could therefore be
regarded as an accurate representation of the amount
of peptide within the sample.
Brieﬂy, 10 mg platelet lysates from each subject
underwent in-gel enzymic digestion before PlA1/A2
peptides were quantiﬁed with reference to a 200 fmol
spike of isotopically distinct synthetic peptides.29
Analyses were performed sequentially on a Vantage
triple stage quadrupole mass spectrometer (Thermo),
with regular quality control samples. Data processing
was performed using Pinpoint v1.0 (Thermo), and
underwent manual interrogation to ensure the presence
of appropriate time-aligned transitions of peptide
fragmentation.
Statistical methods
All data are expressed as mean standard error (SEM),
unless otherwise stated. Analyses of unpaired data were
performed using Mann-Whitney test, with analyses of
categorical data performed using Fisher’s exact test.
The Bonferroni method was used to correct for mul-
tiple comparisons. Agonist-concentration response
curves were plotted and analysed according to a four
parameter logistic equation, where the lower and upper
boundaries were set at 0 and 100%, respectively. Area
under the curve (AUC) values were calculated using the
trapezoid rule from the log-concentration response
curve. Analyses of pooled data based on genotype
were performed using a Friedman test for paired,
non-parametric data. Inter-assay agreement of aspirin
resistance status used Cohen’s Kappa (k).31 All statis-
tical analyses were performed using GraphPad version
4 (Prism), and signiﬁcance was taken as p< 0.05 (two-
tailed).
Results
The proteomics of platelet PlA1/A2 expression
Expression of the PlA1/PlA2 alleles was inferred
through the presence of the corresponding prototypic
peptides (PlA1 peptide: DEALPLGSPRC; PLA2 pep-
tide: DEALPPGSPRC). The assignment of genotype
based on peptide detection above the LMR enabled
healthy subjects to be clearly divided into three
groups: expression of only the wild-type peptide
(PlA1/A1; n¼ 16), expression of only the mutant pep-
tide (PlA2/A2; n¼ 1) and expression of both wild-type
and mutant peptides (PlA1/A2; n¼ 8) (Figure 2). There
was no signiﬁcant diﬀerence in the measured expression
of PlA1/A2 peptides in heterozygous subjects within the
healthy cohort.
In the patient cohort, genotyping of subjects based
on peptide expression was similarly unequivocal, with
69 patients identiﬁed as homozygous for wild-type, two
patients homozygous for mutant and 19 patients het-
erozygous (Table 1). The overall prevalence for carriage
of the PlA2 allele was 28% (32% in Caucasian individ-
uals) when the cohorts were combined.
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Patients who carried the PlA2 allele did not generally
diﬀer signiﬁcantly from PlA1 homozygotes in either bio-
logical/haematological proﬁles (Table 2) or general char-
acteristics (Table 3). Carriers of the PlA2 allele were
noted to have reduced low density lipoprotein (LDL)
concentrations when compared to PlA1 homozygotes,
but this was not signiﬁcant following Bonferroni correc-
tion for multiple comparisons. Carriage of the PlA2
allele has been previously identiﬁed as a mechanism for
neonatal thrombocytopenia.7 Within this adult popula-
tion, carriers of the PlA2 allele did not have an increased
odds ratio for thrombocytopenia (OR 0.82 for platelet
count< 150 109/L, 95% CI 0.21–3.26; p¼ 0.284).
In heterozygous subjects, no signiﬁcant diﬀerences
were observed between expression of the PlA1 and
PlA2 peptides in healthy subjects (ratio PlA1/PlA2
1.12 0.01; p¼ 0.245), but a signiﬁcant diﬀerence was
observed in the patients cohort (ratio PlA1/PlA2
1.17 0.02, p¼ 0.023), the ratio of PlA1/A2 expression
in heterozygotes being signiﬁcantly greater in the
patient cohort than in the healthy cohort (p¼ 0.013)
(Figure 3).
Carriage of the PlA2 allele and platelet function
testing in the patient cohort
Analysis of platelet function by Optimul revealed signiﬁ-
cant diﬀerences in aggregation between PlA1 homozy-
gotes and PlA2 homozygotes at higher concentrations
of ADP, adrenaline, collagen, ristocetin, TRAP-6 and
U46619. Optimul agonist-concentration response curves
were plotted according to a four parameter logistic equa-
tion for all agonists except AA, where inhibition of plate-
let aggregation by aspirin therapy did generate suﬃcient
data (Figure 4).
Analysis of agonist-concentration response curve
parameters revealed a signiﬁcant increase in maximal
aggregation for PlA2 homozygotes versus PlA1 homo-
zygotes irrespective of agonist used (all p< 0.05), but
signiﬁcant results were not consistently observed for
analyses of AUC, Hill slope and half-maximum eﬀect-
ive concentration (EC50). To increase the power of
these analyses to identify any diﬀerences in global
Table 2. Biochemical and haematological profiles based on carriage of PlA2 allele.
Parameter PlA1/A1 (n¼ 69) PlA2 carriers (n¼ 21) Significance (p*)
Sodium (mmol/L) 139 0.3 138 0.7 0.372
Potassium (mmol/L) 4.4 0.0 4.4 0.1 0.983
Creatinine (mmol/L) 89 2.7 96 7.4 0.279
HDL cholesterol (mmol/L) 1.4 0.1 1.5 0.1 0.486
LDL cholesterol (mmol/L) 2.2 0.1 1.7 0.1 0.029
HbA1c (mmol/mol) 45 2.3 42 3.3 0.564
Haemoglobin (g/L) 140 0.1 139 0.3 0.809
White blood cells (109/L) 7.3 0.2 6.6 0.4 0.154
Platelets(109/L) 199 6.3 189 8.6 0.405
*Significant p values following Bonferroni correction for multiple comparisons.
HbA1c: glycated haemoglobin; HDL: high density lipoprotein; LDL: low density lipoprotein.
Figure 2. Peptide expression in healthy subjects based on
inferred genotype.
Scatter plot showing the results from peptide quantification in
healthy subjects for PlA1/A1 (n¼ 16), PlA1/A2 (n¼ 8) and PlA2/
A2 (n¼ 1) genotypes. Open circles represent the PlA1 peptide
and filled circles the PlA2 peptide. Dotted line indicates the lower
limit of measuring range for the PlA1/A2 peptides, above which
peptide quantification can be reliably determined.
Table 1. Frequency of PlA2 allele expression.
Ethnicity
Healthy cohort
(n¼ 25)
Patient cohort
(n¼ 90)
Cohorts combined
(n¼ 115)
Caucasian 18.0 12.7 13.9
Asian 2.0 – 0.4
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platelet reactivity between the genotypes, data for
all agonists (with the exception of AA) were pooled
using the mean results for each parameter. The ration-
ale for this pooled approach is that if the mutant allele
does indeed modulate platelet reactivity through the
activity of GPIIIa, then the aﬀect should be observed
irrespective of agonist used as the GPIIb/IIIa complex
represents the ﬁnal common pathway of platelet aggre-
gation. This approach identiﬁed signiﬁcant diﬀerences
between the genotypes for all parameters except EC50,
with PlA2 homozygotes demonstrating an increased
AUC and Hill slope in addition to the higher maximum
aggregation already observed (Table 4).
Association between carriage of the PlA2 allele
and aspirin resistance
Twelve patients were identiﬁed as aspirin-resistant by
AA-induced LTA (13.3%), of which none were carriers
of the PlA2 allele. Fourteen patients were identiﬁed as
aspirin-resistant by ADP-induced LTA (15.6%), of
which two were carriers of the PlA2 allele. Inter-assay
agreement on the assignment of aspirin resistance
status as identiﬁed by ADP-induced LTA was poor
(k¼ 0.192, 95% CI 0.064 to 0.447).
Discussion
Meta-analyses have shown that carriage of the PlA2
allele of GPIIIa is a risk factor for myocardial infarc-
tion and ischaemic stroke, but there remains uncer-
tainty as to the aetiology of this increased risk.11,12
To date, all published studies have assessed PlA1/A2
status using genetic techniques, with the underlying
assumption that subjects labelled as heterozygous had
equal expression of the corresponding proteins within
their platelets in accordance with Mendelian rules
of inheritance. However, with the identiﬁcation of
X-chromosome inactivation in females, imprinting of
some autosomal genes and preferential expression
of certain single nucleotide polymorphisms, it is clear
that Mendelian gene expression is not absolute and that
carriage of heterozygous alleles does not always result
in equal expression of the proteins they encode.32–34
Here, we have developed an LC-MS/MS assay to
enable the absolute quantiﬁcation of platelet PlA1/A2
peptides and to assess whether Mendelian rules of
Table 3. Patient characteristics based on carriage of PlA2 allele.
Parameter PlA1/A1 (n¼ 69) PlA2 carriers (n¼ 21) Significance (p*)
Sex
Male 65 (94%) 19 (90%) 0.621
Female 4 (6%) 2 (10%)
Age (years) 67.8 1.2 69.0 1.7 0.618
Body mass index (kg/m2) 28.2 0.6 26.8 0.8 0.217
Ethnicity
Caucasian 65 (94%) 21 (100%) 0.569
Asian 4 (6%) –
Smoking status
Current smoker 4 (6%) 2 (10%) 0.817
Ex-smoker 32 (46%) 9 (43%)
Never smoker 35 (48%) 10 (47%)
Blood pressure (mmHg)
Systolic 137 2.2 140 3.6 0.583
Diastolic 77 1.3 80 2.2 0.313
*Significant p values following Bonferroni correction for multiple comparisons.
Figure 3. Box and whisker plot for PlA1:PlA2 peptide expres-
sion in heterozygote subjects.
*p< 0.05
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expression do indeed apply to this important
polymorphism.
Exploration of the performance characteristics of the
assay demonstrated that it was ‘ﬁt for purpose’ to
accurately quantify the PlA1/A2 peptides, as measures
of both reproducibility and precision conformed to
accepted standards.30 The LMR for both peptides
was 20 fmol and, as shown in Figure 2, this facilitated
a clear division of genotypes based on the presence of
the corresponding peptides. In the healthy cohort, there
Figure 4. Impact of carriage of the PlA2 allele on platelet function as assessed by Optimul.
A-G) Optimul aggregation in response to agonist. Statistical analyses displayed compare PlA1 homozygotes to PlA2 homozygotes for
individual agonist concentrations. Individual data points plotted as mean SEM. PlA1/A1 (n¼ 69), PlA1/A2 (n¼ 19), PlA2/A2 (n¼ 2)
AA: arachidonic acid: ADP: adenosine diphosphate; SEM: standard error; TRAP-6: thrombin receptor activating peptide 6.
6 Journal of the Royal Society of Medicine Cardiovascular Disease 4(0)
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was no signiﬁcant diﬀerence in the expression of
PlA1/A2 peptides in heterozygous subjects clearly indi-
cating that expression does indeed obey Mendelian
rules within this cohort.
The data for the patient cohort were less clear in
regard to obeying Mendelian expression patterns, as
there was a reduced expression of the mutant peptide
when compared to thewild-type in heterozygous individ-
uals. It has previously been observed that both cardio-
vascular disease and aspirin therapy can modulate gene
expression. It is therefore possible that either, or both, of
these mechanisms may be contributing to a down regu-
lation of the mutant allele and a consequent reduction in
cardiovascular risk.35–37 Alternatively, in patients with
stable cardiovascular disease their underlying inﬂamma-
tory phenotype may lead to a preferential activation and
subsequent degradation of mutant ﬁbrinogen receptors
in heterozygous subjects.38 However, the wider inter-
quartile range observed in the patient cohort combined
with a relatively small diﬀerence in the PlA1/PlA2 ratio
suggests that these data are more likely to represent vari-
ation in sample storage, preparation and analysis
between the cohorts. Further investigation in a larger
cohort is required to explore the PlA1/PlA2 ratio further.
The prevalence of the PlA2 allele has been previously
suggested to be approximately 0.15 in Caucasian popu-
lations, based on a study of 200 random Dutch blood
donors.10 Here, we have observed a similar prevalence
of the mutant allele in Caucasian patients (0.13), with
none of the four Asian patients identiﬁed as carriers.
Carriage of the PlA2 allele in the patient cohort gave
rise to a demonstrable diﬀerence in platelet function as
assessed by the Optimul assay, which enabled us to
produce a comprehensive assessment of how carriage
of the PlA2 allele impacts on platelet function in
response to a broad range of agonists. The increase in
platelet aggregation for PlA2 homozygotes was shown
to be not restricted to a single pathway of platelet acti-
vation, but rather was observed all agonists under
investigation (other than AA). The demonstrable
aspirin-medicated inhibition of platelet COX-1 in all
carriers of the PlA2 allele impaired the analysis of
how the PlA1/A2 polymorphism may modulate AA-
induced aggregation.
The use of Optimul also enabled the plotting of
agonist-concentration response curves and the analysis
of aggregation responses in their totality rather than
solely a comparison of isolated data points. Variation
within the patient cohort (including demographics, bio-
chemical/haematological parameters, prescribed medi-
cation and co-morbidities) combined with only two
PlA2 homozygous subjects meant that analyses of
curve parameters were underpowered when considered
for each agonist separately. However, the pooling of
data for all agonists revealed a signiﬁcant increase in
maximal aggregation, AUC and Hill slope for PlA2
homozygotes.
These ﬁndings support the hypothesis that carriage
of the PlA2 allele does indeed modulate platelet reactiv-
ity through a ﬁnal common pathway, and the putative
mechanism of enhanced ligand binding in the presence
of this mutation is compatible with the observed
increase in Hill slope. The signiﬁcant increase in aggre-
gation was only observed for PlA2 homozygotes, but
we hypothesise that a moderate increase in aggregation
would also be observed for heterozygotes within an
appropriately powered data set. The diﬀerence in
aggregation response cannot be explained by either dif-
fering haematological/biological proﬁles or patient
characteristics. However, the identiﬁcation of only
two PlA2 homozygotes is a clear limitation of this
study, and a larger dataset would be required to cor-
roborate these ﬁndings.
Carriage of the PlA2 allele was not observed to confer
an increased risk of aspirin resistance, deﬁned by either
AA-induced or ADP-induced LTA. This is perhaps
unsurprising given the importance of shear forces to
the phenotype determined by the polymorphism and
Table 4. Analysis of agonist-concentration response curves.
Parameter
Genotype
Significance (p)PlA1/A1 PlA1/A2 PlA2/A2
Maximum aggregation (%) 78 5 77 5 91 4 0.008*
AUC (Arb) 103 16 106 16 122 20 0.029*
Hill slope 2.88 1.05 3.41 1.40 3.693 1.14 0.012*
logEC50 (Arb) 5.44 0.50 5.49 0.49 5.42 0.49 0.142*
Note: Pooled data for all agonist-concentration response curves generated by Optimul in response to ADP, collagen,
adrenaline, ristocetin, U46619 and TRAP-6. Arbitrary units (Arb) presented for logEC50 due to variation in units between
agonists. Data presented as mean SEM.
*p< 0.05
ADP: adenosine diphosphate; AUC: area under curve; EC50: half-maximum effective concentration; SEM: standard error;
TRAP-6: thrombin receptor-activating peptide 6.
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indicates substantial issues with most previously pub-
lished studies investigating the association between
aspirin resistance and this polymorphism.20 The poor
inter-assay agreement on aspirin resistance status further
highlights the controversies surrounding the precise
identiﬁcation of this phenomenon.39
Aside from the ﬁndings presented here, this work
raises a broader issue about how one should approach
the analysis of platelet function within a clinical envir-
onment. LTA is the current ‘gold standard’, but in pre-
viously published work appears to provide an inaccurate
assessment of platelet function for carriers of a common
genetic polymorphism. These ﬁndings may be the result
of diﬀerences in assay mechanics when compared to
Optimul or possibly represent the limitations of a tech-
nique that precludes plotting agonist-concentration
response curves for multiple agonists. Further investiga-
tion in a healthy population should further categorise of
how the choice of platelet function assay may impact on
the observed eﬀect of the polymorphism.
Conclusions
Platelet PlA1/A2 peptides are readily quantiﬁable by
LC-MS/MS and appear to obey the rules of
Mendelian expression, with homozygosity for the
mutant allele appearing to confer a global increase in
platelet reactivity. The pairing of proteomic and plate-
let function data as we have demonstrated here has
potential for the future understanding of platelet aggre-
gation responses.
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